Ocera Therapeutics is a biopharmaceutical company developing novel therapeutics for patients with acute and chronic liver diseases.
Ocera is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need.Ocera's HE clinical development efforts include a recently completed Phase 2b clinical trial, STOP-HE, which evaluated the safety and efficacy of intravenously-administered OCR-002 in resolving neurocognitive symptoms of acute HE in hospitalized patients with elevated ammonia. Ocera is preparing to meet with the FDA later this year to review the IV program and discuss potential development paths forward.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 3, 2015 | Post-IPO Debt | $20M | 3 | — | — | Detail |
Nov 6, 2013 | Post-IPO Equity | $28M | 8 | — | — | Detail |
Mar 30, 2012 | Post-IPO Debt | $1.50M | — | — | — | Detail |
Apr 4, 2011 | IPO | $54M | — | — | — | Detail |
Feb 20, 2008 | Series C | $35.50M | 9 | Greenspring Associates | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Sofinnova Investments | Yes | Series B |
Greenspring Associates | — | Post-IPO Debt |
Oxford Finance LLC | — | Post-IPO Debt |
Silicon Valley Bank | — | Post-IPO Debt |
Deerfield Partners | — | Post-IPO Equity |
Great Point Partners | — | Post-IPO Equity |
InterWest Partners | — | Post-IPO Equity |
QVT Financial | — | Post-IPO Equity |
RA Capital Management | — | Post-IPO Equity |
Three Arch Partners | — | Post-IPO Equity |